Patents by Inventor Pan-Chyr Yang

Pan-Chyr Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11214774
    Abstract: The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. The PINK1-CTD polypeptide inhibits, prevents and/or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressing cancer therapy.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: January 4, 2022
    Assignees: National Taiwan University, Academia Sinica
    Inventors: Pan-Chyr Yang, Pei-Ying Lin, Bo-Tsang Huang
  • Publication number: 20210373200
    Abstract: The present invention provides a device for generating an abrupt autofocusing beam, comprising a light source module, a metasurface phase modulating element, and a focus lens, wherein the light source module generates an incident light beam, the metasurface modulating element has a first optical receiving surface for receiving the incident light beam, and an optical emitting surface having a plurality of dielectric nano-structures formed thereon for modulating the incident light beam into a diffracted light beam wherein the plurality of nano-structures respectively corresponding to optical-phase mask patterns, and the focus lens is arranged at a side of the optical receiving surface for performing optical Fourier transform of the diffracted light beam obtained from the metasurface phase modulating element.
    Type: Application
    Filed: June 2, 2021
    Publication date: December 2, 2021
    Inventors: Yuan Luo, Din Ping Tsai, Pan-Chyr Yang
  • Publication number: 20210254072
    Abstract: Nucleic acid aptamers that bind to tumor necrosis factor alpha (TNF). Also provided herein are pharmaceutical compositions comprising such anti-TNF aptamers and methods for the using the same for therapeutic and diagnostic applications, for example, alleviating liver injury and monitoring presence of TNF in vivo or in vitro.
    Type: Application
    Filed: December 21, 2018
    Publication date: August 19, 2021
    Inventors: Pan-Chyr Yang, Wei-Yun Lai, Jen-Wei Wang
  • Publication number: 20210115409
    Abstract: An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 22, 2021
    Applicant: NATIONAL TAIWAN UNIVERSITY
    Inventors: Pan-Chyr Yang, Huei-Wen Chen, Wan-Jiun Chen
  • Patent number: 10888568
    Abstract: The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and/or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: January 12, 2021
    Assignee: National Yang Ming University
    Inventors: Chi-Ying Huang, Jane Hsiao, Pan-Chyr Yang, Meng-Hua Lee
  • Patent number: 10865388
    Abstract: An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: December 15, 2020
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Pan-Chyr Yang, Huei-Wen Chen, Wan-Jiun Chen
  • Publication number: 20200330449
    Abstract: Compounds of Formula (I) and methods for treating, delaying, and/or preventing the adverse effects of proliferative diseases, such as cancers including, for example, lung cancer, breast cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, head and neck cancer, or leukemia (e.g., cancer resistant to treatment by one or more microtubule-targeting agents, e.g., cancer resistant to multiple drugs associated with P-glycoprotein (P-gp) overexpression). Methods of inhibiting polymerization of a cancer cell microtubule in a subject in need thereof or a cell, tissue, or biological sample, binding p-tubulin, inhibiting microtubule assembly and, inducing apoptosis in a cancer cell resistant to multiple drugs in a tissue, biological sample, or subject. Pharmaceutical compositions, kits, and methods of using the compounds for treating any of the target diseases described herein.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 22, 2020
    Inventors: Rong-Jie CHEIN, Pan-Chyr YANG, Chi-Huey WONG, Ming-Shiu LIN, Ting-Jen CHENG, Ting-Hung CHOU
  • Patent number: 10765681
    Abstract: The present disclosure provides compounds of Formulas (I?) and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: September 8, 2020
    Assignees: Academia Sinica, National Taiwan University
    Inventors: Chi-Huey Wong, Pan-Chyr Yang, Jim-Min Fang, Szu-Hua Pan, Ting-Jen R. Cheng, Ling-Wei Li
  • Publication number: 20200095233
    Abstract: The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).
    Type: Application
    Filed: February 28, 2017
    Publication date: March 26, 2020
    Applicants: Academia Sinica, National Taiwan University
    Inventors: Chi-Huey Wong, Pan-Chyr Yang, Rong-Jie Chein, Szu-Hua Pan, Ting-Jen R. Cheng
  • Patent number: 10584341
    Abstract: Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: March 10, 2020
    Assignees: Academia Sinica, National Taiwan University
    Inventors: Pan-Chyr Yang, Wei-Yun Lai, Bo-Tsang Huang
  • Patent number: 10533179
    Abstract: Aptamers that bind to and inhibit CTLA-4 and uses thereof in enhancing immune activities, and treating cancer and HIV infection are provided.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: January 14, 2020
    Assignees: Academia Sinica, National Taiwan University, Taipei Medical University
    Inventors: Konan Peck, Pan-Chyr Yang, Yi-Chung Chang, Bo-Tsang Huang, Shauh-Der Yeh
  • Publication number: 20190346445
    Abstract: Provided herein are methods and kits for analyzing a sample such as a biological sample obtained from a subject having, suspected of having, or being at risk for a cancer to assess presence of cancer stem cells in the sample, which is indicative of poor cancer prognosis.
    Type: Application
    Filed: January 3, 2018
    Publication date: November 14, 2019
    Applicant: National Taiwan University
    Inventors: Pan-Chyr Yang, Huei-Wen Chen, Wan-Jiun Chen
  • Publication number: 20190275345
    Abstract: Ironized viral particles such as ironized adeno-associated viral particles, which may carry a photosensitizer such as a KillerRed protein, and uses thereof in light-triggered virotherapy against tumor.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 12, 2019
    Applicants: Academia Sinica, National Taiwan University
    Inventors: Pan-Chyr Yang, S.-Ja Tseng, Zi-Xian Liao
  • Patent number: 10329570
    Abstract: Aptamers that bind to and antagonize programmed cell death protein 1 (PD-1). Also provided herein are pharmaceutical compositions comprising such anti-PD-1 aptamers and methods for using the same for promoting T cell proliferation, treating cancer or infectious diseases, such as human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 25, 2019
    Assignees: Academia Sinica, National Taiwan University
    Inventors: Pan-Chyr Yang, Yi-Chung Chang, Wei-Yun Lai
  • Publication number: 20190070191
    Abstract: The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and/or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine.
    Type: Application
    Filed: October 29, 2018
    Publication date: March 7, 2019
    Inventors: Chi-Ying Huang, Jane Hsiao, Pan-Chyr Yang, Meng-Hua Lee
  • Publication number: 20180369249
    Abstract: The present disclosure provides compounds of Formulas (I?) and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases.
    Type: Application
    Filed: February 3, 2017
    Publication date: December 27, 2018
    Applicants: Academia Sinica, National Taiwan University
    Inventors: Chi-Huey Wong, Pan-Chyr Yang, Jim-Min Fang, Szu-Hua Pan, Ting-Jen R. Cheng, Ling-Wei Li
  • Patent number: 10155993
    Abstract: Disclosed herein is a method of determining whether a subject having or is at risk of developing lung cancer. The presence of the SNP locus of rs193100333, which corresponds to a mutation on YAP1 protein with a substitution of an arginine to a tryptophan at position 331, indicates the subject has or is at risk of developing lung cancer. Accordingly, also disclosed herein is a kit for facilitating the detection of the SNP locus of rs193100333.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: December 18, 2018
    Assignee: National Taiwan University
    Inventors: Ker-Chau Li, Bing-Ching Ho, Sung-Liang Yu, Gee-Chen Chang, Hsuan-Yu Chen, Pan-Chyr Yang
  • Publication number: 20180258431
    Abstract: Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.
    Type: Application
    Filed: August 31, 2016
    Publication date: September 13, 2018
    Applicants: Academia Sinica, National Taiwan University
    Inventors: Pan-Chyr Yang, Wei-Yun Lai, Bo-Tsang Huang
  • Publication number: 20180230435
    Abstract: An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.
    Type: Application
    Filed: September 24, 2014
    Publication date: August 16, 2018
    Inventors: Pan-Chyr Yang, Huei-Wen Chen, Wan-Jiun Chen
  • Publication number: 20180112192
    Abstract: The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. The PINK1-CTD polypeptide inhibits, prevents and/or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressing cancer therapy.
    Type: Application
    Filed: May 2, 2016
    Publication date: April 26, 2018
    Inventors: Pan-Chyr Yang, Pei-Ying Lin, Bo-Tsang Huang